Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitro

Prostate Cancer and Prostatic Diseases

Volumn 15, Issue 3, 2012, Pages 250-255

  Mani, J ^a   Vallo, S ^a   Barth, K ^a   Makarevic J ^a   Juengel, E ^a   Bartsch, G ^a   Wiesner, C ^a   Haferkamp, A ^a   Blaheta, R A ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

growth; integrins; invasion; zoledronic acid

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BETA1 INTEGRIN; BETA4 INTEGRIN; CELL PROTEIN; CYCLIN E; PROTEIN P27; SCLEROPROTEIN; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL ADHESION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; UPREGULATION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMIDAZOLES; MALE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84865331399     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2012.9     Document Type: Article

References (35)

1. Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N et al. Metastatic patterns of prostate cancer: An autopsy study of 1589 patients. Hum Pathol 2000; 31: 578 - 583.
2. Ho JW. Bisphosphonate stimulation of osteoblasts and osteoblastic metastasis as a mechanism of hypocalcaemia. Med Hypotheses 2012; 78: 377 - 379.
3. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458 - 1468.
4. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogencontaining bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13: 581 - 589.
5. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. Longterm efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879 - 882.
6. Hung TT, Chan J, Russell PJ, Power CA. Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model. PLoS One 2011; 6: E19389.
7. Di Salvatore M, Orlandi A, Bagala' C, Quirino M, Cassano A, Astone A et al. Antitumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Prolif 2011; 44: 139 - 146.
8. Koto K, Murata H, Kimura S, Horie N, Matsui T, Nishigaki Y et al. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents. Oncol Rep 2010; 24: 233 - 239.
9. Sewing L, Steinberg F, Schmidt H, Göke R. The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis 2008; 13: 782 - 789.
10. Li YY, Chang JW, Chou WC, Liaw CC, Wang HM, Huang JS et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer 2008; 59: 180 - 191.
11. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61: 2602 - 2608.
12. Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 2003; 170: 246 - 252.
13. Dumon JC, Journé F, Kheddoumi N, Lagneaux L, Body JJ. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol 2004; 45: 521 - 528.
14. Clyburn RD, Reid P, Evans CA, Lefley DV, Holen I. Increased anti-tumour effects of doxorubicin and ZA in prostate cancer cells in vitro: Supporting the benefits of combination therapy. Cancer Chemother Pharmacol 2010; 65: 969 - 978.
15. Almubarak H, Jones A, Chaisuparat R, Zhang M, Meiller TF, Scheper MA. ZA directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers. J Carcinog 2011; 10: 2.
16. Karabulut B, Karaca B, Atmaca H, Kisim A, Uzunoglu S, Sezgin C et al. Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and ZA in hormone-refractory prostate cancer cell lines. Mol Biol Rep 2011; 38: 249 - 259.
17. Sonnemann J, Bumbul B, Beck JF. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate ZA against prostate cancer cells in vitro. Mol Cancer Ther 2007; 6: 2976 - 2984.
18. Lin P, Sun X, Feng T, Zou H, Jiang Y, Liu Z et al. ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway. Mol Cell Biochem 2012; 359: 235 - 243.
19. Kannaiyan R, Manu KA, Chen L, Li F, Rajendran P, Subramaniam A et al. Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3K/Akt signaling pathways. Apoptosis 2011; 16: 1028 - 1041.
20. Marra M, Santini D, Meo G, Vincenzi B, Zappavigna S, Baldi A et al. Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. Int J Cancer 2009; 125: 2004 - 2013.
21. Pandhare-Dash J, Mantri CK, Gong Y, Chen Z, Dash C. XMRV accelerates cellular proliferation, transformational activity, and invasiveness of prostate cancer cells by downregulating p27(Kip1). Prostate 2011; e-pub ahead of print 19 September 2011; doi:10.1002/pros.21491.
22. Roy S, Singh RP, Agarwal C, Siriwardana S, Sclafani R, Agarwal R. Downregulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype. Cell Cycle 2008; 7: 1828 - 1835.
23. Ananthanarayanan V, Deaton RJ, Amatya A, Macias V, Luther E, Kajdacsy-Balla A et al. Subcellular localization of p27 and prostate cancer recurrence: Automated digital microscopy analysis of tissue microarrays. Hum Pathol 2011; 42: 873 - 881.
24. Romics I, Ba'nfi G, Sze'kely E, Krena'cs T, Szende B. Expression of p21(waf1/cip1), p27 (kip1), p63 and androgen receptor in low and high Gleason score prostate cancer. Pathol Oncol Res 2008; 14: 307 - 311.
25. Fang Z, Zhang T, Dizeyi N, Chen S, Wang H, Swanson KD et al. Androgen receptor enhances p27 degradation in prostate cancer cells through rapid and Selective TORC2 activation. J Biol Chem 2012; 287: 2090 - 2098.
26. Moriceau G, Ory B, Mitrofan L, Riganti C, Blanchard F, Brion R et al. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): Pivotal role of the prenylation process. Cancer Res 2010; 70: 10329 - 10339.
27. Morgan TM, Pitts TE, Gross TS, Poliachik SL, Vessella RL, Corey E. RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate 2008; 68: 861 - 871.
28. Zaman MH, Trapani LM, Sieminski AL, Mackellar D, Gong H, Kamm RD et al. Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis. Proc Natl Acad Sci USA 2006; 103: 10889 - 10894.
29. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000; 60: 2949 - 2954.
30. Montague R, Hart CA, George NJ, Ramani VA, Brown MD, Clarke NW. Differential inhibition of invasion and proliferation by bisphosphonates: Anti-metastatic potential of Zoledronic acid in prostate cancer. Eur Urol 2004; 46: 389 - 401.
31. Goel HL, Moro L, King M, Teider N, Centrella M, McCarthy TL et al. Beta1 integrins modulate cell adhesion by regulating insulin-like growth factor-II levels in the microenvironment. Cancer Res 2006; 66: 331 - 342.
32. Ramirez NE, Zhang Z, Madamanchi A, Boyd KL, O'Rear LD, Nashabi A et al. The a2b1 integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest 2011; 121: 226 - 237.
33. Bonaccorsi L, Carloni V, Muratori M, Salvadori A, Giannini A, Carini M et al. Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype. Endocrinology 2000; 141: 3172 - 3182.
34. Drake JM, Barnes JM, Madsen JM, Domann FE, Stipp CS, Henry MD. ZEB1 coordinately regulates laminin-332 and \{beta\}4 integrin expression altering the invasive phenotype of prostate. J Biol Chem 2010; 285: 33940 - 33948.
35. Kovacevic Z, Sivagurunathan S, Mangs H, Chikhani S, Zhang D, Richardson DR. The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms. Carcinogenesis 2011; 32: 732 - 740.